Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Fulvestrant × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 116 Neoplasm Metastasis 16 Ovarian Neoplasms 13 Endometrial Neoplasms 9 Neoplasms 8 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Advanced Breast Cancer 4 Neoplasms by Site 3 Hereditary Sensory and Autonomic Neuropathies 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Breast Diseases 3 Breast Cancer Metastatic 3 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Multiple Endocrine Neoplasia Type 1 2 Melanoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Lobular 2 Advanced Solid Tumors 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Salivary Gland Neoplasms 1

Interventions

Letrozole 1 Fulvestrant 1 Epirubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡